𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of lonidamine on human malignant gliomas: Biochemical studies

✍ Scribed by Marco G. Paggi; Carmine M. Carapella; Maurizio Fanciulli; Carlo Carlo; Sergio Giorno; Gabriella Zupi; Bruno Silvestrini; Antonio Caputo; Aristide Floridi

Publisher
Springer US
Year
1988
Tongue
English
Weight
466 KB
Volume
6
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

✦ Synopsis

Lonidamine (LND) has been shown to inhibit tumor aerobic glycolysis. Its effect was evaluated on several human astrocytomas at different degrees of malignancy; a correlation was found between LDN effect on lactate production and tumor malignancy: in grade I and II astrocytomas LND stimulates lactate production, while in grade III, IV and glioblastoma multiforme lactate production is inhibited. In an attempt to explain this different behaviour, hexokinase content and compartmentation was evaluated in astrocytomas from fresh operatory specimens and from cultured cells as well, observing a significative correlation between malignancy, hexokinase activity, percent of mitochondrially-bound hexokinase and LND effect. The results justify from a biochemical point of view the role of LND as a 'non-conventional' agent in multimodality combined treatment for malignant gliomas.

πŸ“œ SIMILAR VOLUMES

Effect of synthetic matrix-metalloprotei
Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas In vitro
✍ Joerg-Christian Tonn; Siglinde Kerkau; Anne Hanke; Hakim Bouterfa; Justus G. Mue πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 276 KB

Glioma invasion into the surrounding brain tissue is still a major obstacle for any therapeutical approach. As in other solid tumors, matrix-metalloproteases (MMPs) have been suggested as being involved. The aim of this study was to evaluate whether the use of MMP inhibitors to target the protease-m

Effect of HECNU in malignant supratentor
Effect of HECNU in malignant supratentorial gliomas β€” a phase II study
✍ P. Georges; S. Przedborski; J. Brotchi; M. Chatel; D. GΓ©douin; J. Hildebrand πŸ“‚ Article πŸ“… 1988 πŸ› Springer US 🌐 English βš– 453 KB

Forty adults with recurring brain gliomas were treated with HECNU 130 mg/m 2, given i.v. every 5 to 6 weeks (mean 5.4) and corticosteroids. According to the response to treatment, patients were divided in 3 groups: 1. Group I included 8 pts (20%) with objective remission, defined as a clear-cut clin